533 related articles for article (PubMed ID: 20836726)
1. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
[TBL] [Abstract][Full Text] [Related]
4. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
5. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
6. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
Bhattacharya SM; Jha A
Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
10. The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age.
Fábregues F; Castelo-Branco C; Carmona F; Guimerá M; Casamitjana R; Balasch J
Gynecol Endocrinol; 2011 Apr; 27(4):216-24. PubMed ID: 20500102
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome.
Dursun F; Güven A; Yıldız M
J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):55-60. PubMed ID: 26761944
[TBL] [Abstract][Full Text] [Related]
12. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
13. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
14. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin.
Tomova A; Deepinder F; Robeva R; Kirilov G; Mechandjiev Z; Kumanov P
Horm Metab Res; 2011 Sep; 43(10):723-7. PubMed ID: 21932178
[TBL] [Abstract][Full Text] [Related]
15. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
16. Is the suppressive effect of cyproterone acetate on serum anti-Müllerian-hormone levels in women with polycystic ovary syndrome stronger than under oral contraceptive pill?
Plouvier P; Peigné M; Gronier H; Robin G; Catteau-Jonard S; Dewailly D
Gynecol Endocrinol; 2016 Aug; 32(8):612-616. PubMed ID: 26890873
[TBL] [Abstract][Full Text] [Related]
17. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
18. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study.
Naka KK; Kalantaridou SN; Bechlioulis A; Kravariti M; Kazakos N; Katsouras CS; Tsatsoulis A; Michalis LK
Gynecol Endocrinol; 2011 Sep; 27(9):615-21. PubMed ID: 21329419
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
20. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome.
Carlsen SM; Vanky E; Fleming R
Hum Reprod; 2009 Jul; 24(7):1732-8. PubMed ID: 19342396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
